recombinant vectors based on the modified vaccinia virus Ankara (MVA) as vaccines against leishmaniasis.

recombinant vectors based on the modified vaccinia virus Ankara (MVA) as vaccines against leishmaniasis. The vectors of the invention contain sequences encoding the LACK protein, preferably inserted into the hemagglutinin locus and under the control of a promoter allowing its expression during the infection cycle of the virus. Are safe, stable vectors, which give rise to a potent immune response conferring protection against leishmaniasis, which are good candidates for use in vaccination against this disease, especially in humans.